Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.

Med Sci (Basel) · 2025 · PMC12452606 · PMID 40981198

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The observation of a “plateau” in the progression-free survival curve for lorlatinib, with a 5-year PFS rate of 60%, is highly significant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.